Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Trimmed by Wells Fargo & Company MN

Wells Fargo & Company MN lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 12.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 152,508 shares of the biopharmaceutical company's stock after selling 21,533 shares during the period. Wells Fargo & Company MN owned about 0.14% of Regeneron Pharmaceuticals worth $108,636,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Willner & Heller LLC grew its holdings in shares of Regeneron Pharmaceuticals by 3.9% in the 4th quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company's stock worth $284,000 after acquiring an additional 15 shares during the period. OLD Second National Bank of Aurora grew its holdings in Regeneron Pharmaceuticals by 0.5% in the fourth quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company's stock valued at $2,025,000 after purchasing an additional 15 shares during the last quarter. Rakuten Securities Inc. increased its position in shares of Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 15 shares in the last quarter. TD Private Client Wealth LLC raised its stake in shares of Regeneron Pharmaceuticals by 9.6% during the 4th quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock worth $122,000 after buying an additional 15 shares during the last quarter. Finally, Manchester Capital Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 12.6% in the 4th quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company's stock worth $115,000 after buying an additional 18 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on REGN. Robert W. Baird cut their target price on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating for the company in a research report on Wednesday, February 5th. Truist Financial cut their price objective on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating for the company in a research report on Wednesday, January 8th. Canaccord Genuity Group started coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a "hold" rating and a $165.00 target price on the stock. Citigroup reduced their price objective on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 28th. Finally, Leerink Partners upgraded Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and lifted their price objective for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $966.88.

Regeneron Pharmaceuticals Stock Up 1.4 %

Shares of Regeneron Pharmaceuticals stock traded up $7.79 during trading hours on Friday, hitting $554.18. 1,170,894 shares of the company's stock traded hands, compared to its average volume of 707,716. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a twelve month low of $525.99 and a twelve month high of $1,211.20. The stock has a 50 day simple moving average of $659.94 and a 200-day simple moving average of $753.23. The company has a market cap of $60.59 billion, a PE ratio of 14.48, a PEG ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter last year, the firm earned $11.86 EPS. Regeneron Pharmaceuticals's quarterly revenue was up 10.3% on a year-over-year basis. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were issued a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.64%. Regeneron Pharmaceuticals's dividend payout ratio is presently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.